Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orismilast for hidradenitis suppurativa
2021-000049-42Phase 2Completed
- Sponsor
- Zealand University Hospital
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of orismilast in hidradenitis suppurativa (HS), sponsored by Zealand University Hospital. Primary endpoint: Percent change from baseline in abscess and nodule count at Week 16. Started Feb 2021; status: completed.
02
Drugs
orismilast
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on 2021-000049-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000049-42.